PTGX

MKT CAP:$6B

Protagonist Therapeutics Inc

Market Cap

$6B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$98.03+$10.85 (+12.45%)

Jun 8, 2026

52W High $105.9852W Low $49.70

Company Details

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of ...

CEO

—

IPO Date

Aug 11, 2016

Website

www.protagonist-inc.com

Key Metrics TTM

Revenue

$74M

-64.4% YoY

Net Income

-$115M

EPS (Diluted)

Free Cash Flow

-$116M

Revenue / Share

$1.05

Gross Margin

99.5%

Operating Margin

-192.4%

Net Margin

-154.9%

FCF Margin

-157.0%

P/S

82.4x

P/E

Earnings Reports

Q1 2026

May 5, 2026

$56M+99.0%

FY 2025

Feb 25, 2026

$46M-89.4%

Q4 2025

Feb 25, 2026

$7M-95.6%

Q3 2025

Nov 6, 2025

$5M+0.8%

Q2 2025

Aug 6, 2025

$6M+33.1%

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee